The incidence and trends of proteinuria, azotemia and hypertension in cats receiving toceranib phosphate

IF 1.9 2区农林科学 Q2 VETERINARY SCIENCES

Journal of Feline Medicine and Surgery Pub Date : 2024-09-17 DOI:10.1177/1098612x241266418

Kimberly Williams, Valerie MacDonald-Dickinson, Arata Matsuyama

{"title":"The incidence and trends of proteinuria, azotemia and hypertension in cats receiving toceranib phosphate","authors":"Kimberly Williams, Valerie MacDonald-Dickinson, Arata Matsuyama","doi":"10.1177/1098612x241266418","DOIUrl":null,"url":null,"abstract":"ObjectivesThis retrospective study aimed to determine the incidence and trends of proteinuria, elevations in serum creatinine and urea, and systolic blood pressure in cats undergoing treatment with toceranib.MethodsIn total, 32 cats treated with toceranib for malignancies were analyzed. Cats were included if urinalysis and urine protein:creatinine ratio (UPC) measurements were available at 28 days (T1) and 56 days (T2) after starting the treatment. Cats with concurrent lower urinary tract disease, including urinary tract malignancy, were excluded. Friedman’s ANOVA compared variables between time points, and the Spearman test assessed the correlation between treatment duration and UPC.ResultsThe median starting dose of toceranib was 2.68 mg/kg (range 1.7–3.9). In total, 15 (46.9%) cats received concurrent non-steroidal anti-inflammatory drugs. The most commonly treated tumors were oral squamous cell carcinoma (n = 10) and mast cell tumor (n = 5). None of the 32 cats developed progressive proteinuria or azotemia during the follow-up period (median 56 days; range 56–336). Notably, UPC and serum creatinine were significantly lower at T2 compared with baseline ( P = 0.012 and 0.001, respectively). Among the four cats with baseline proteinuria, UPC decreased over time with or without concurrent telmisartan treatment (n = 2). All four of these cats experienced a reduction in tumor size with toceranib concurrently with their decreased UPC. There was no significant correlation between UPC and the duration of toceranib treatment ( P = 0.089). Blood pressure was not significantly different over the assessed time points.Conclusions and relevanceThe incidence of proteinuria, renal azotemia and hypertension in cats treated with toceranib for neoplasia appears to be low. Toceranib may be a viable treatment option even in cats with pre-existing proteinuria or renal disease, with careful monitoring of trends recommended.","PeriodicalId":15851,"journal":{"name":"Journal of Feline Medicine and Surgery","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Feline Medicine and Surgery","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1177/1098612x241266418","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

ObjectivesThis retrospective study aimed to determine the incidence and trends of proteinuria, elevations in serum creatinine and urea, and systolic blood pressure in cats undergoing treatment with toceranib.MethodsIn total, 32 cats treated with toceranib for malignancies were analyzed. Cats were included if urinalysis and urine protein:creatinine ratio (UPC) measurements were available at 28 days (T1) and 56 days (T2) after starting the treatment. Cats with concurrent lower urinary tract disease, including urinary tract malignancy, were excluded. Friedman’s ANOVA compared variables between time points, and the Spearman test assessed the correlation between treatment duration and UPC.ResultsThe median starting dose of toceranib was 2.68 mg/kg (range 1.7–3.9). In total, 15 (46.9%) cats received concurrent non-steroidal anti-inflammatory drugs. The most commonly treated tumors were oral squamous cell carcinoma (n = 10) and mast cell tumor (n = 5). None of the 32 cats developed progressive proteinuria or azotemia during the follow-up period (median 56 days; range 56–336). Notably, UPC and serum creatinine were significantly lower at T2 compared with baseline ( P = 0.012 and 0.001, respectively). Among the four cats with baseline proteinuria, UPC decreased over time with or without concurrent telmisartan treatment (n = 2). All four of these cats experienced a reduction in tumor size with toceranib concurrently with their decreased UPC. There was no significant correlation between UPC and the duration of toceranib treatment ( P = 0.089). Blood pressure was not significantly different over the assessed time points.Conclusions and relevanceThe incidence of proteinuria, renal azotemia and hypertension in cats treated with toceranib for neoplasia appears to be low. Toceranib may be a viable treatment option even in cats with pre-existing proteinuria or renal disease, with careful monitoring of trends recommended.

查看原文本刊更多论文

接受磷酸托塞瑞尼治疗的猫咪蛋白尿、氮质血症和高血压的发生率及趋势

目的这项回顾性研究旨在确定接受托塞瑞尼治疗的猫咪蛋白尿、血清肌酐和尿素升高以及收缩压的发生率和趋势。方法共分析了 32 只接受托塞瑞尼治疗的恶性肿瘤猫咪。如果在开始治疗后的 28 天（T1）和 56 天（T2）能进行尿液分析和尿蛋白肌酐比（UPC）测量，则将这些猫纳入研究范围。不包括同时患有下尿路疾病（包括尿路恶性肿瘤）的猫。弗里德曼方差分析比较了各时间点之间的变量，斯皮尔曼检验评估了治疗持续时间与 UPC 之间的相关性。共有 15 只（46.9%）猫同时服用了非甾体抗炎药。最常治疗的肿瘤是口腔鳞状细胞癌（10 只）和肥大细胞瘤（5 只）。在随访期间（中位数为 56 天；范围为 56-336 天），32 只猫中没有一只出现进行性蛋白尿或氮质血症。值得注意的是，与基线相比，UPC 和血清肌酐在 T2 阶段明显降低（P = 0.012 和 0.001）。在基线蛋白尿的四只猫中，无论是否同时接受替米沙坦治疗，UPC都会随着时间的推移而下降（n = 2）。这四只猫在接受托塞瑞尼治疗的同时，UPC也有所下降。UPC与托瑞替尼治疗持续时间之间无明显相关性（P = 0.089）。结论和相关性在使用托塞瑞尼治疗肿瘤的猫中，蛋白尿、肾性氮质血症和高血压的发生率似乎很低。即使对已有蛋白尿或肾病的猫来说，托克瑞尼也可能是一种可行的治疗选择，建议仔细监测其趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Feline Medicine and Surgery 农林科学-兽医学

CiteScore

3.90

自引率

17.60%

发文量

254

审稿时长

8-16 weeks

期刊介绍： JFMS is an international, peer-reviewed journal aimed at both practitioners and researchers with an interest in the clinical veterinary healthcare of domestic cats. The journal is published monthly in two formats: ‘Classic’ editions containing high-quality original papers on all aspects of feline medicine and surgery, including basic research relevant to clinical practice; and dedicated ‘Clinical Practice’ editions primarily containing opinionated review articles providing state-of-the-art information for feline clinicians, along with other relevant articles such as consensus guidelines.